Trial Profile
A phase II, open-label, multicentre, randomised, comparator study of substitution with tenofovir [tenofovir disoproxil fumarate] or abacavir in HIV-1 infected individuals, with a viral load less than 50 copies/mL, receiving a thymidine analogue (zidovudine or stavudine) as part of their highly active antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary) ; Abacavir
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms RAVE
- Sponsors Gilead Sciences
- 21 Apr 2008 New trial record.